134 related articles for article (PubMed ID: 38378397)
1. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
2. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
3. The NKG2D axis: an emerging target in cancer immunotherapy.
Lazarova M; Steinle A
Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
[TBL] [Abstract][Full Text] [Related]
4. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
5. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
7. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
9. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology.
Secchiari F; Nuñez SY; Sierra JM; Ziblat A; Regge MV; Raffo Iraolagoitia XL; Rovegno A; Ameri C; Secin FP; Richards N; Ríos Pita H; Vitagliano G; Rico L; Mieggi M; Frascheri F; Bonanno N; Blas L; Trotta A; Friedrich AD; Fuertes MB; Domaica CI; Zwirner NW
Oncoimmunology; 2022; 11(1):2104991. PubMed ID: 35936986
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
[TBL] [Abstract][Full Text] [Related]
13. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
14. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
15. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
16. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
[TBL] [Abstract][Full Text] [Related]
17. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.
Baragaño Raneros A; Martín-Palanco V; Fernandez AF; Rodriguez RM; Fraga MF; Lopez-Larrea C; Suarez-Alvarez B
Genes Immun; 2015; 16(1):71-82. PubMed ID: 25393931
[TBL] [Abstract][Full Text] [Related]
18. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
19. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
[TBL] [Abstract][Full Text] [Related]
20. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
